论文部分内容阅读
目的探讨子宫腺肌病伴痛经患者应用不同剂量米非司酮的治疗效果及对不良反应发生的影响。方法选取周口市中心医院收治的67例子宫腺肌病伴痛经患者,按随机数表法分为观察组34例和对照组33例。对照组予以12.5 mg/d米非司酮治疗,观察组予以6.25 mg/d米非司酮治疗,均治疗3个月。观察比较两组临床治疗效果及治疗前后血清黄体生成素(LH)、卵泡刺激素(FSH)、孕酮(P)水平变化情况,并统计两组不良反应发生情况。结果观察组治疗总有效率为91.18%(31/34)低于对照组的96.97%(32/33),两组比较差异无统计学意义(P>0.05);治疗前,两组内分泌各指标水平对比,差异无统计学意义(P>0.05);观察组治疗前后LH、FSH、P水平差异无统计学意义(P>0.05),治疗后两组LH及FSH水平比较差异无统计学意义(P>0.05);对照组治疗后P水平较治疗前显著降低,且低于观察组治疗后,差异有统计学意义(P<0.05);观察组不良反应发生率为2.94%(1/34),低于对照组24.24%(8/33),差异有统计学意义(P<0.05)。结论低剂量米非司酮可有效改善子宫腺肌病伴痛经患者临床症状,降低不良反应发生率,对患者内分泌功能影响小。
Objective To investigate the therapeutic effect of different doses of mifepristone in patients with adenomyosis accompanied by dysmenorrhea and its effect on adverse reactions. Methods 67 cases of adenomyosis with dysmenorrhea admitted to Zhoukou Central Hospital were divided into observation group (34 cases) and control group (33 cases) by random number table. The control group was treated with 12.5 mg / d mifepristone, while the observation group was treated with 6.25 mg / d mifepristone for 3 months. The effects of clinical treatment and the changes of serum LH, FSH and P levels before and after treatment were observed and compared. The incidence of adverse reactions was also calculated. Results The total effective rate in the observation group was 91.18% (31/34), which was lower than that in the control group (96.97%, 32/33). There was no significant difference between the two groups (P> 0.05) (P> 0.05). The levels of LH, FSH and P in the observation group had no significant difference before and after treatment (P> 0.05). There was no significant difference in the levels of LH and FSH between the two groups after treatment P> 0.05). The P level of the control group after treatment was significantly lower than that before treatment, and the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 2.94% (1/34) , Lower than the control group 24.24% (8/33), the difference was statistically significant (P <0.05). Conclusion Low dose mifepristone can effectively improve the clinical symptoms of patients with adenomyosis and dysmenorrhea, reduce the incidence of adverse reactions, and have little effect on the endocrine function of patients.